Had Canada and Medicago been in a position to be able to launch this product, not only within Canada but also internationally, what would that $150 million go toward? The $172 million, naturally, went to ensuring that we did the R and D, set up the facility and made sure we were ready to produce.
We have now an approved product, which faced some challenges—and we'll get to that—but what was the $150 million specifically earmarked for?